UROTRACTIN ® Pipemidic acid

UROTRACTIN ® is a drug based on pipemidic acid

THERAPEUTIC GROUP: Antibacterial for systemic use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications UROTRACTIN ® Pipemidic acid

UROTRACTIN ® is used in the clinical setting in the treatment of urinary tract infections sustained by microorganisms sensitive to pipemidic acid.

The same medicine was also useful in the prophylaxis of post-operative and post-diagnostic urinary tract infections.

Mechanism of action UROTRACTIN ® Pipemidic acid

UROTRACTIN ® is a drug based on pipemidic acid, antibacterial counted among the first generation fluoroquinolones, effective in the treatment of urinary infections sustained by Gram positive and Gram negative sensitive microorganisms.

Taken orally, pipemidic acid is rapidly absorbed from the gastrointestinal tract, is distributed in organs such as kidney, prostate and intestine, concentrating at the urinary level following glomerular filtration.

It is precisely at this level that the active principle performs the maximum therapeutic efficacy, permeating the membranes of bacterial cells and inhibiting enzymes involved in the replication mechanisms of bacterial DNA such as DNA-gyrase and DNA-topoisomerases, and thus controlling proliferation and the spread of the pathogen.

The aforementioned mechanism of action, also extended to plasmidic DNA, allows to control the spread of antibiotic resistance genes, thus maintaining a particularly high therapeutic sensitivity.

Studies carried out and clinical efficacy

PHOSPHOMYCIN VS PIPEMIDIC ACID IN THE TREATMENT OF URINARY VIE INFECTIONS

Primary Aten. 1992 Dec; 10 (9): 1007-12.

Interesting study that compares the efficacy and safety of treatment with pipemidic acid and fosfomycin in urinary infections, showing that fosfomycin can be an equally effective drug in these cases.

ADVERSE REACTIONS TO PIPEMIDIC ACID

J Dermatol. 1991 Jan; 18 (1): 59-60.

Case report reporting the appearance of skin lesions due to hypersensitivity during treatment with pipemidic acid in a 71-year-old patient.

PIPEMIDIC ACID AND RECURRENT CISTITES

Ann Urol (Paris). 1989; 23 (1): 53-7.

Clinical trial conducted for several months on women suffering from recurrent cystitis which demonstrates the good efficacy and good degree of safety of pipemidic acid in the treatment of these often relapsing pathological conditions.

Method of use and dosage

UROTRACTIN ®

Hard capsules of 200 - 400 mg of pipemidic acid.

The dosing schedule useful for the treatment of urinary tract infections should be defined by the physician based on the physio-pathological and clinical characteristics of the patient.

Generally the intake of 400 mg of pipemidic acid twice a day, preferably away from meals, is sufficient to guarantee a prompt remission of the symptoms.

Warnings UROTRACTIN ® Pipemidic acid

The use of UROTRACTIN ® should be preceded by a careful medical examination in order to assess the prescriptive appropriateness and the possible presence of contraindications to the use of pipemidic acid.

During therapy with UROTRACTIN ® it is advisable to avoid direct exposure to ultraviolet radiation due to the photosensitising power of pipemidic acid, potentially responsible for burns and rashes.

PREGNANCY AND BREASTFEEDING

The use of UROTRACTIN ® during pregnancy should be limited to cases of real need and clearly under strict medical supervision.

These limitations are imposed by the absence of studies able to fully characterize the safety profile of the drug for fetal health.

Interactions

During therapy with UROTRACTIN ® it would be useful to avoid the simultaneous intake of preparations, foods and active ingredients containing divalent metals, such as magnesium, aluminum, calcium, iron and zinc due to the chelating capacity of the latter against pipemidic acid.

Different studies also show pharmacologically relevant interactions with erythromycin, glibenclamide, probenecid and H2 antagonists.

Contraindications UROTRACTIN ® Pipemidic acid

The use of UROTRACTIN ® is contraindicated in patients who are hypersensitive to the active substance or to any of its excipients.

Undesirable effects - Side effects

Pipemidic acid therapy could cause nausea, vomiting, diarrhea, abdominal pain, dyspepsia and only rarely more serious side effects such as pseudomembranous colitis or dermatological and hepatotoxic adverse reactions.